Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis ; volume:19 ; number:1 ; day:3 ; month:1 ; year:2019 ; pages:1-9 ; date:12.2019
BMC infectious diseases ; 19, Heft 1 (3.1.2019), 1-9, 12.2019
- Creator
-
Al-Mutairi, Noura M.
Ahmad, Suhail
Mokaddas, Eiman
Eldeen, Hanaa S.
Joseph, Susan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-018-3638-z
- URN
-
urn:nbn:de:101:1-2019020822130659358681
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Al-Mutairi, Noura M.
- Ahmad, Suhail
- Mokaddas, Eiman
- Eldeen, Hanaa S.
- Joseph, Susan
- SpringerLink (Online service)
Other Objects (12)
Multidrug-resistant tuberculosis
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Correction: Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Tuberculosis out of control : strategies to fight multidrug-resistant tuberculosis
Nomogram to predict multidrug-resistant tuberculosis
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
Characteristics of multidrug-resistant tuberculosis in Namibia
Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families
Multidrug-resistant tuberculosis
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Correction: Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Tuberculosis out of control : strategies to fight multidrug-resistant tuberculosis
Nomogram to predict multidrug-resistant tuberculosis
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
Characteristics of multidrug-resistant tuberculosis in Namibia
Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families
Multidrug-resistant tuberculosis
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Correction: Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Tuberculosis out of control : strategies to fight multidrug-resistant tuberculosis
Nomogram to predict multidrug-resistant tuberculosis
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
Characteristics of multidrug-resistant tuberculosis in Namibia